GLAXO
Invest with MTF
Invest Now
Invest in GlaxoSmithKline Pharmaceuticals with 3.24X leverage
Performance
- Low
- ₹2,405
- High
- ₹2,489
- 52 Week Low
- ₹1,968
- 52 Week High
- ₹3,516
- Open Price₹2,445
- Previous Close₹2,445
- Volume75,210
- 50 DMA₹2,457.97
- 100 DMA₹2,550.98
- 200 DMA₹2,627.93
Investment Returns
- Over 1 Month + 0.98%
- Over 3 Month -4.01%
- Over 6 Month -7.23%
- Over 1 Year + 12.49%
Smart Investing Starts Here Start SIP with GlaxoSmithKline Pharmaceuticals for Steady Growth!
GlaxoSmithKline Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 44.1
- PEG Ratio
- 1.1
- Market Cap Cr
- 42,081
- P/B Ratio
- 24.6
- Average True Range
- 75.79
- EPS
- 56.27
- Dividend Yield
- 1.7
- MACD Signal
- -20.61
- RSI
- 57.08
- MFI
- 39.79
GlaxoSmithKline Pharmaceuticals Financials
GlaxoSmithKline Pharmaceuticals Technicals
EMA & SMA
Current Price
₹2,484.00
+
39.4
(1.61%)
- Bearish Moving Average 5
- Bullish Moving Average 11
- 20 Day
- ₹2,410.78
- 50 Day
- ₹2,457.97
- 100 Day
- ₹2,550.98
- 200 Day
- ₹2,627.93
Resistance and Support
2459.33
- R3 2,597.67
- R2 2,543.33
- R1 2,513.67
- S1 2,429.67
- S2 2,375.33
- S3 2,345.67
GlaxoSmithKline Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
GlaxoSmithKline Pharmaceuticals F&O
About GlaxoSmithKline Pharmaceuticals
- NSE Symbol
- GLAXO
- BSE Symbol
- 500660
- Managing Director
- Mr. B Akshikar
- ISIN
- INE159A01016
Similar Stocks to GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals FAQs
GlaxoSmithKline Pharmaceuticals share price is ₹2,484 As on 08 February, 2026 | 16:11
The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹42080.5 Cr As on 08 February, 2026 | 16:11
The P/E ratio of GlaxoSmithKline Pharmaceuticals is 44.1 As on 08 February, 2026 | 16:11
The PB ratio of GlaxoSmithKline Pharmaceuticals is 24.6 As on 08 February, 2026 | 16:11
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.